Health And Pharma10d
MATTERHORN Trial: Imfinzi Shows Significant Survival Benefit in Gastric and GEJ Cancer Treatment
The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
Health And Pharma12d
How SkinJect's Microneedle Technology Could Transform the Treatment of Skin Cancer
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...
Health And Pharma13d
A Breakthrough in Personalizing Lung Cancer Therapy with the GO Chip for Tumor Monitoring
The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...
Health And Pharma13d
FDA Approves Tislelizumab Plus Chemotherapy for PD-L1+ Metastatic Esophageal Cancer
The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...
Health And Pharma14d
CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...
Health And Pharma18d
Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment
The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate for certain patients with metastatic breast ...
healthandpharma20d
KEYTRUDA Receives Priority FDA Review for Perioperative Use in ES Head and Neck Cancer
KEYTRUDA® (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives FDA priority review based on KEYNOTE-689 results. The trial showed improved ...